Medicines Patent Pool

Medicines Patent Pool
Name	Medicines Patent Pool
Founded	2010
Headquarters	Geneva, Switzerland
Type	Non-profit organization
Purpose	Access to medicines, intellectual property management
Leader title	Executive Director

Medicines Patent Pool

The Medicines Patent Pool is a United Nations-backed public health organization created to improve access to essential treatments by negotiating voluntary licensing and patent pooling for patented medicines. It operates within a global network that includes World Health Organization, United Nations, UNAIDS, Bill & Melinda Gates Foundation, and national agencies such as Swiss Agency for Development and Cooperation and US Food and Drug Administration.

Overview

The organization negotiates voluntary licenses with patent holders like Roche, Gilead Sciences, ViiV Healthcare, GlaxoSmithKline, and Johnson & Johnson to enable generic manufacture for low- and middle-income countries, working alongside stakeholders including Médecins Sans Frontières, Clinton Health Access Initiative, UNICEF, World Bank, and regional bodies such as African Union and Pan American Health Organization. Its mandate touches therapeutic areas such as HIV/AIDS, tuberculosis, hepatitis C, and recently COVID-19 technologies in coordination with actors like COVAX, Gavi, CEPI, UNAIDS Programme Coordinating Board, and national health ministries of India, South Africa, and Brazil.

History and Development

Founded in 2010 following advocacy from UNITAID and key figures from UNAIDS and World Health Organization, the organization built on precedents including the WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property and debates around TRIPS Agreement flexibilities highlighted by 2001 Doha Declaration on the TRIPS Agreement and Public Health and campaigns led by Access to Medicines Movement, Doctors Without Borders and activists in India and South Africa. Early licences with manufacturers like Gilead Sciences and Boehringer Ingelheim shaped its model, while legal contexts such as rulings from the European Court of Justice and policy shifts in countries like China and Brazil influenced its expansion into new therapeutic classes.

Objectives and Activities

Core objectives include increasing affordability through voluntary licences, facilitating technology transfer with partners like Cipla, Hetero Drugs, Sun Pharmaceutical Industries, and Mylan (now Viatris), and supporting regulatory approval via collaborative work with European Medicines Agency, US Food and Drug Administration, and national regulators in South Africa and Nigeria. Activities cover patent landscaping, licensing negotiations, capacity-building with entities such as Medicines for All Institute and Bill & Melinda Gates Foundation, pooled patent databases, and partnerships for formulation development with research institutions like University of Cape Town, Imperial College London, and Johns Hopkins University.

Governance and Funding

The governance structure involves a board drawing representatives from international organizations including UNICEF, World Bank, UNAIDS, and civil society groups such as Partners In Health and Oxfam International, with operational leadership engaging legal teams experienced in intellectual property from firms that have worked on cases before the World Trade Organization and the European Patent Office. Funding streams include grants from UNITAID, philanthropic donors like Wellcome Trust, Bill & Melinda Gates Foundation, multilateral contributions from Global Fund to Fight AIDS, Tuberculosis and Malaria, and project funding involving P4H Network and bilateral donors from Sweden, Germany, and Norway.

Impact and Criticisms

Supporters cite expanded access to antiretrovirals and pediatric formulations through agreements with ViiV Healthcare and Gilead Sciences, leading to uptake in countries such as Kenya, Uganda, Mozambique, and India, and endorsement by agencies like UNAIDS and WHO. Critics from groups including Médecins Sans Frontières and academic commentators at Harvard University and London School of Economics argue that voluntary licensing may entrench patent-holder control, limit coverage compared with compulsory licences under the TRIPS Agreement, and fall short in addressing barriers identified in reports from Human Rights Watch. Legal scholars citing cases in India and policy analyses from Chatham House and Brookings Institution debate trade-offs between innovation incentives involving firms like Pfizer and access objectives.

Partnerships and Agreements

Notable licences and partnerships have involved originators such as Gilead Sciences, ViiV Healthcare, and Mylan (ViVatis), with generic producers like Cipla, Hetero, Strides Pharma, and Zhejiang Huahai Pharmaceutical producing versions for multiple countries, coordinated alongside regulators including Health Canada and ANVISA. Collaboration with initiatives such as COVID-19 Technology Access Pool (C-TAP), WHO Solidarity Trial, and humanitarian organizations like Red Cross and Save the Children expanded scope to vaccines, diagnostics, and manufacturing know-how through technology transfer with institutes like AstraZeneca manufacturing partners and academic spinouts from Karolinska Institutet.

Future Directions

Future priorities include expanding mandates into neglected areas like long-acting formulations, paediatric medicines, diagnostics and vaccines by engaging innovators such as Moderna, BioNTech, AstraZeneca, and Sanofi, strengthening regional manufacturing in Africa CDC supported hubs like the African Medicines Agency, and deepening collaboration with financing mechanisms like the Global Fund and Gavi while remaining responsive to global health emergencies as established during COVID-19 and informing policy dialogues at forums such as the United Nations General Assembly and the World Health Assembly.

Category:Health organizations